-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MusclePharm (OTCMKTS:MSLP) and AbCellera Biologics (NASDAQ:ABCL) Head to Head Contrast
MusclePharm (OTCMKTS:MSLP) and AbCellera Biologics (NASDAQ:ABCL) Head to Head Contrast
MusclePharm (OTCMKTS:MSLP – Get Rating) and AbCellera Biologics (NASDAQ:ABCL – Get Rating) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.
Analyst Ratings
This is a breakdown of recent ratings and target prices for MusclePharm and AbCellera Biologics, as provided by MarketBeat.
Get MusclePharm alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MusclePharm | 0 | 0 | 0 | 0 | N/A |
AbCellera Biologics | 0 | 0 | 7 | 0 | 3.00 |
AbCellera Biologics has a consensus price target of $28.50, suggesting a potential upside of 101.27%. Given AbCellera Biologics' higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than MusclePharm.
Volatility and Risk
MusclePharm has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500.Institutional and Insider Ownership
15.5% of MusclePharm shares are owned by institutional investors. Comparatively, 44.4% of AbCellera Biologics shares are owned by institutional investors. 60.7% of MusclePharm shares are owned by company insiders. Comparatively, 30.3% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares MusclePharm and AbCellera Biologics' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
AbCellera Biologics | $375.20 million | 10.80 | $153.46 million | $0.79 | 17.92 |
AbCellera Biologics has higher revenue and earnings than MusclePharm. MusclePharm is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares MusclePharm and AbCellera Biologics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
MusclePharm | -38.51% | N/A | -169.56% |
AbCellera Biologics | 41.17% | 21.15% | 16.40% |
Summary
AbCellera Biologics beats MusclePharm on 11 of the 13 factors compared between the two stocks.
About MusclePharm
(Get Rating)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
About AbCellera Biologics
(Get Rating)
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
MusclePharm (OTCMKTS:MSLP – Get Rating) and AbCellera Biologics (NASDAQ:ABCL – Get Rating) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.
穆斯克莱姆制药(场外交易代码:MSLP-GET评级)和艾伯赛乐生物(纳斯达克:ABCL-GET评级)都是消费品公司,但哪一家业务更好?我们将根据两家公司的分析师推荐、机构持股、估值、收益、风险、股息和盈利能力的强弱对它们进行比较。
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and target prices for MusclePharm and AbCellera Biologics, as provided by MarketBeat.
这是由MarketBeat提供的MusclePharm和AbCellera Biologics最近的评级和目标价格细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MusclePharm | 0 | 0 | 0 | 0 | N/A |
AbCellera Biologics | 0 | 0 | 7 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
穆斯克尔帕姆 | 0 | 0 | 0 | 0 | 不适用 |
AbCellera生物制品公司 | 0 | 0 | 7 | 0 | 3.00 |
AbCellera Biologics has a consensus price target of $28.50, suggesting a potential upside of 101.27%. Given AbCellera Biologics' higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than MusclePharm.
AbCellera Biologics的一致目标价为28.5美元,暗示潜在上涨101.27%。考虑到AbCellera Biologics更有可能的上行空间,分析师们显然认为AbCellera Biologics比MusclePharm更有利。
Volatility and Risk
波动性和风险
Institutional and Insider Ownership
机构和内部人持股
15.5% of MusclePharm shares are owned by institutional investors. Comparatively, 44.4% of AbCellera Biologics shares are owned by institutional investors. 60.7% of MusclePharm shares are owned by company insiders. Comparatively, 30.3% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
该公司15.5%的股份由机构投资者持有。相比之下,AbCellera Biologics 44.4%的股份由机构投资者持有。MusclePharm 60.7%的股份由公司内部人士持有。相比之下,AbCellera Biologics 30.3%的股份由公司内部人士持有。强大的机构持股表明,捐赠基金、对冲基金和大型基金管理公司相信,一家公司有望实现长期增长。
Earnings & Valuation
收益与估值
This table compares MusclePharm and AbCellera Biologics' revenue, earnings per share and valuation.
该表格比较了MusclePharm和AbCellera Biologics的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
AbCellera Biologics | $375.20 million | 10.80 | $153.46 million | $0.79 | 17.92 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
穆斯克尔帕姆 | 5,004万美元 | 0.07 | -1287万美元 | ($0.58) | -0.17 |
AbCellera生物制品公司 | 3.752亿美元 | 10.80 | 1.5346亿美元 | $0.79 | 17.92 |
AbCellera Biologics has higher revenue and earnings than MusclePharm. MusclePharm is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
AbCellera Biologics的收入和收益比MusclePharm更高。MusclePharm的市盈率低于AbCellera Biologics,这表明它目前是两只股票中更负担得起的一只。
Profitability
盈利能力
This table compares MusclePharm and AbCellera Biologics' net margins, return on equity and return on assets.
此表比较了MusclePharm和AbCellera Biologics的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
MusclePharm | -38.51% | N/A | -169.56% |
AbCellera Biologics | 41.17% | 21.15% | 16.40% |
净利润率 | 股本回报率 | 资产回报率 | |
穆斯克尔帕姆 | -38.51% | 不适用 | -169.56% |
AbCellera生物制品公司 | 41.17% | 21.15% | 16.40% |
Summary
摘要
AbCellera Biologics beats MusclePharm on 11 of the 13 factors compared between the two stocks.
AbCellera Biologics在两只股票之间进行比较的13个因素中有11个击败了MusclePharm。
About MusclePharm
关于MusclePharm
(Get Rating)
(获取评级)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
公司在美国和国际上开发、制造、营销和分销运动营养品和营养补充剂。该公司提供一系列高性能粉末、胶囊、片剂、凝胶和随时可用的零食。该公司的MusclePharm品牌产品组合包括战斗蛋白粉和战斗挤压蛋白棒;以及支链氨基酸、肌酸、谷氨酰胺、肉碱、共轭亚油酸、鱼油、多种维生素和其他产品等基本补充剂。该公司还提供FitMisse品牌的运动营养产品,这些产品主要是为女性身体制定的,以支持女性在体重管理、瘦肌肉质量、身体成分以及一般健康和健康方面的需求;以及FitMisse Energy和FitMisse Energy品牌的功能能量饮料。它向各种运动员和健身爱好者销售其产品。该公司成立于2006年,总部设在内华达州拉斯维加斯。
About AbCellera Biologics
关于AbCellera Biologics
(Get Rating)
(获取评级)
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.开发抗体发现平台。它的全栈、人工智能支持的抗体发现平台搜索和分析自然免疫系统的数据库,以发现可以开发为药物的抗体。截至2021年12月31日,该公司有156个已完成、正在进行或与36个合作伙伴签订合同的发现项目。AbCellera Biologics Inc.与礼来公司有研究合作和许可协议。该公司成立于2012年,总部位于加拿大温哥华。
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
接受MusclePharm日报的新闻和评级-在下面输入您的电子邮件地址,即可通过MarketBeat.com的免费每日电子邮件时事通讯收到对MusclePharm和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧